查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
原代细胞培养市场：2023年至2028年预测
市场调查报告书
商品编码
1410103

原代细胞培养市场：2023年至2028年预测

Primary Cell Culture Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

原代细胞培养市场预计在预测期内复合年增长率为 8.59%。

在生物医学研究中，原代细胞培养是直接分离和培养来自活体组织和器官的细胞的重要技术。透过解剖或切片检查从组织中提取细胞，然后在适当的培养基中培养以保留其生理意义和天然特性。随着研究各种细胞群的异质性增加，该方法为理解生物过程、药理反应和毒理学结果提供了更准确的模型。

原代细胞培养市场的成长动力

推动原代细胞培养市场扩大的主要因素是糖尿病、癌症、感染疾病、自体免疫疾病、心血管疾病和肾臟疾病等慢性疾病发生率的上升。此外，由于这些患者疾病的增加而增加的研究工作正在推动原代细胞培养物的广泛普及。

提高细胞和基因疗法开发的使用率

对个人化治疗的需求不断增加，导致再生医学的广泛使用。这项因素进一步激发了原代细胞培养产业的活力。使用细胞和基因疗法治疗癌症、遗传异常和自体免疫疾病等疾病具有广阔的前景。原代细胞培养对其生长有重要作用。它是操纵或改变细胞或基因以恢復或增强其功能的行为。

癌症流行

由于癌症的流行，对原代细胞培养的需求正在扩大。例如，世界卫生组织预测，到2030年，全球癌症相关死亡人数将增加到近1,700万人。此外，根据 2021 年 2 月的 ACS 日誌报道，2020 年全球整体有 1,020 万人因癌症相关死亡，新增约 1,930 万癌症病例。因此，随着全球癌症发生率的上升，对创新治疗方法的需求将会增加，预计这将推动原代细胞培养市场占有率的成长。

对酵素降解的日益偏好预计将推动市场发展

由于酵素消化方法比替代初代细胞分离技术具有减少培养损伤、快速处理和代表性样本高功率等优点，因此原代细胞培养市场的偏好正在上升。透过使用多种类型的酶，可以降解组织，同时产生大量初代细胞。此方法所使用的主要酵素是粗胰蛋白酶。因此，酵素降解是原代细胞培养分离培养程序中最优选的方法，因为它对细胞的负面影响低且产量高。

使用原代细胞进行 3D 培养的生物医学研究进展

原代细胞被认为是生物学上真实的，因为它们与原始供体组织几乎完美匹配。这表明 3D 细胞构建体中使用的原代细胞比细胞株更有能力创建体内多细胞环境的生理相关模拟。原代细胞经常用于 3D 培养，因为它们比传统细胞株提供更准确的观察。

增加原代细胞培养在动物细胞的使用

原代细胞培养的成长进一步受到动物源原代细胞在疫苗开发中的广泛使用的推动。动物细胞，包括小鼠、大鼠和猪，经过充分研究和表征，是各种科学应用的有用资源。是研究疾病原因、开发新药、进行毒性试验的重要模型。

北美预计将占据主要市场占有率/原代细胞培养市场的区域分析

由于医疗成本高昂、老年人口不断增加、慢性病发病率上升以及政府融资增加，预计北美将主导全球原代细胞培养产业。此外，由于干细胞移植相关成本降低，预计亚太地区将出现强劲成长，导致需求增加和大量研究和开发。再生医学、干细胞研究和组织工程应用的重大进展也带动了亚太地区细胞和基因疗法开发和生产的繁荣。

市场主要发展

  • 2023 年 4 月，AnaBios 将收购 Cell Systems，以增加可用于药物研发研究的人类细胞类型的数量。
  • 2023 年 2 月，赛默飞世尔科技与製造公司 Celltrio 合作，为客户提供全自动细胞培养系统。
  • 2022年3月，高纯度Kupffer细胞将加入BioIVT的人类原代肝细胞库中，以支持肝病新药的研发。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章原代细胞培养市场：副产品

  • 介绍
  • 原代细胞
  • 试剂和补充品
  • 培养基

第六章原代细胞培养市场：依分离方法

  • 介绍
  • 外植体法
  • 酵素降解
  • 机械分离
  • 其他的

第七章原代细胞培养市场：依细胞类型

  • 介绍
  • 动物细胞
  • 人体细胞

第八章原代细胞培养市场：依应用分类

  • 介绍
  • 细胞和基因疗法的发展
  • 疫苗生产
  • 模型系统
  • 病毒学
  • 产前诊断
  • 其他的

第九章原代细胞培养市场：依地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第十章竞争环境及分析

  • 主要企业及策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 供应商竞赛矩阵

第十一章 公司简介

  • Thermo Fisher Scientific, Inc.
  • Lonza
  • Merck KGaA
  • Corning Incorporated
  • Danaher
  • PromoCell GmbH
  • ATCC
  • FUJIFILM Irvine Scientific, Inc.
  • Mattek
  • Axol Bioscience Ltd
简介目录
Product Code: KSI061615763

The primary cell culture market is estimated to grow at a CAGR of 8.59% during the forecast period.

In biomedical research, primary cell culture is an essential technique that involves isolating and cultivating cells directly originating from living tissues or organs. Cells are extracted from tissues by dissection or biopsy, and they are then grown in an appropriate medium to retain their physiological significance and original properties. Through increased heterogeneity in the study of varied cell populations, the method offers a more accurate model for comprehending biological processes, pharmacological reactions, and toxicological consequences.

Growth drivers in the primary cell culture market

The main driver fueling the primary cell culture market's expansion is the rising incidence of chronic diseases such as diabetes mellitus, cancer, infections, autoimmune disorders, cardiovascular diseases, and nephrological diseases. Furthermore, increased research efforts as a result of this rise in illness among patients have encouraged the widespread use of primary cell cultures.

Rising utilization in cell and gene therapy development

The need for personalized treatments is rising, which can be linked to the expanding usage of regenerative medicine. This factor is further fueling the primary cell culture industry. The use of cell and gene therapies to treat ailments including cancer, genetic abnormalities, and autoimmune diseases holds considerable promise. The primary cell culture plays a crucial part in their growth. They entail the manipulation and alteration of cells or genes to restore or increase their function.

Growing prevalence of cancer

The necessity for primary cell culture is expanding as a result of the growing prevalence of cancer. . For instance, according to WHO forecasts, by 2030, the number of cancer-related fatalities will have increased to almost 17 million worldwide. Additionally, according to ACS Journals from February 2021, there were 10.2 million cancer-related fatalities and around 19.3 million new cases of cancer globally in 2020. Thus, as cancer rates rise globally, there will be an increasing need for innovative therapies, which is expected to fuel primary cell culture market share.

Increasing preference for enzymatic degradation is anticipated to drive the market

The primary cell culture market share is rising due to a strong preference for the enzymatic degradation method over alternative primary cell separation techniques because of its advantages including decreased culturing damage, quick processing, and high output of a representative sample. With the use of several types of enzymes, the tissue is disaggregated while producing a high output of primary cells. The main enzyme employed in this method is crude trypsin. Enzymatic disaggregation is, therefore, the most favoured approach in primary cell culture separation and culture procedures since it has less of a negative impact on the cells and produces a higher yield.

Advancement in biomedical research in 3D cultures using primary cells

Primary cells are regarded to be biologically realistic due to their almost perfect match to the original donor tissue. This demonstrates that primary cells utilized in 3D cell structures are more capable than cell lines of producing physiologically appropriate simulations of multicellular environments found in vivo. Primary cells are frequently employed in 3D cultures because they yield findings that are more accurate than those of traditional cell lines.

Increasing use of primary cell culture in animal cells

The primary cell culture growth is further being driven by the expanding use of animal-origin primary cells for vaccine development. Since animal cells have been well examined and characterized, including those from mice, rats, and pigs, they are useful resources for a variety of scientific applications. They are crucial models for researching disease causes, creating new drugs, and conducting toxicity tests.

North America is predicted to hold a significant market share/ Regional analysis of primary cell culture market

North America is anticipated to dominate the global primary cell culture industry due to its high healthcare costs, expanding elderly population, rising chronic illness rates, and increased government financing. Moreover, the Asia Pacific region is predicted to experience strong growth as a result of the decreased costs connected with stem cell transplantation in the area, which has increased demand and included significant R&D. With major developments in regenerative medicine, stem cell research, and tissue engineering applications, there has also been a boom in the development and production of cell and gene treatments in Asia Pacific region.

Market Key Developments

  • In April 2023, AnaBios bought Cell Systems to increase the range of human cells available for drug research.
  • In February 2023, Thermo Fisher Scientific, Inc. established a partnership with manufacturing firm Celltrio to provide its clients with a fully automated cell culture system.
  • In March 2022, High-purity Kupffer cells were added to BioIVT's collection of human primary hepatic cells to aid in the research and development of new medications for liver diseases.

Segmentation:

By Product

  • Primary Cells
  • Reagents & Supplements
  • Media

By Separation

  • Explant Method
  • Enzymatic Degradation
  • Mechanical Separation
  • Others

By Cell Type

  • Animal Cells
  • Human Cells

By Application

  • Cell & Gene Therapy Development
  • Vaccine Production
  • Model System
  • Virology
  • Prenatal Diagnosis
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. PRIMARY CELL CULTURE MARKET, BY PRODUCT

  • 5.1. Introduction
  • 5.2. Primary Cells
  • 5.3. Reagents & Supplements
  • 5.4. Media

6. PRIMARY CELL CULTURE MARKET, BY SEPARATION

  • 6.1. Introduction
  • 6.2. Explant Method
  • 6.3. Enzymatic Degradation
  • 6.4. Mechanical Separation
  • 6.5. Others

7. PRIMARY CELL CULTURE MARKET, BY CELL TYPE

  • 7.1. Introduction
  • 7.2. Animal Cells
  • 7.3. Human Cells

8. PRIMARY CELL CULTURE MARKET, BY APPLICATION

  • 8.1. Introduction
  • 8.2. Cell & Gene Therapy Development
  • 8.3. Vaccine Production
  • 8.4. Model System
  • 8.5. Virology
  • 8.6. Prenatal Diagnosis
  • 8.7. Others

9. PRIMARY CELL CULTURE MARKET, BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. United States
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. United Kingdom
    • 9.4.2. Germany
    • 9.4.3. France
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. The Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Israel
    • 9.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. Japan
    • 9.6.2. China
    • 9.6.3. India
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Emerging Players and Market Lucrativeness
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Vendor Competitiveness Matrix

11. COMPANY PROFILES

  • 11.1. Thermo Fisher Scientific, Inc.
  • 11.2. Lonza
  • 11.3. Merck KGaA
  • 11.4. Corning Incorporated
  • 11.5. Danaher
  • 11.6. PromoCell GmbH
  • 11.7. ATCC
  • 11.8. FUJIFILM Irvine Scientific, Inc.
  • 11.9. Mattek
  • 11.10. Axol Bioscience Ltd